HOME >> MEDICINE >> NEWS
NIAID forms network to tackle potentially fatal reaction to smallpox vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today launched the Atopic Dermatitis and Vaccinia Network (ADVN), a nationwide research group that seeks to reduce the risk of eczema vaccinatum (EV), a severe and potentially deadly complication of smallpox immunization. EV occurs almost exclusively in people with a history of atopic dermatitis (AD), a chronic, itchy skin condition commonly referred to as eczema. While uncommon, EV can develop when AD patients are given the smallpox vaccine or come into close personal contact with people who recently received the vaccine. If untreated, EV can kill between 1 to 6 percent of those affected. In children younger than 2 years of age, EV has been estimated to kill up to 30 percent.

"Millions of Americans have a history of atopic dermatitis," says Anthony S. Fauci, M.D., director of NIAID. "Launching this network is an important step toward our goal of helping to protect everyone against the smallpox virus without the risk of life-threatening complications."

"Previous studies suggest that both innate and adaptive immunity are impaired in patients with atopic dermatitis, but the specific defects that increase the likelihood of eczema vaccinatum have yet to be explained," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "The information generated by this network will improve our understanding of the immune responses of these patients and should greatly influence the design of a safer smallpox vaccine."

The ADVN comprises three integrated components: a clinical studies consortium, an animal studies consortium and a statistical and data coordinating center.

The ADVN Clinical Studies Consortium will, among other activities, seek to understand why people with AD have such severe reactions to smallpox vaccine by evaluating their immune responses after natural exposure to less harmf
'"/>

Contact: Paul Williams
pwilliams@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
19-May-2004


Page: 1 2

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID rotavirus vaccine licensed for commercialization
9. Second NIAID SARS vaccine candidate helps mice fend off SARS
10. NIAID vaccine protects against SARS virus infection in mice
11. NIAID Ebola vaccine enters human trial

Post Your Comments:
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... News) -- Measures taken by Firestone officials at the ... have limited the spread of the disease there and ... Natural Rubber Co. provides health services to about 80,000 ... populated communities. Between Aug. 1 and Sept. 23, ... those 80,000 people. That incidence rate of 0.09 percent ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... Oct. 22, 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: ... its novel investigational drug for cancer, is designed for ... side effects. Its oncology focus is on melanoma, breast ... phase 2 trials of PV-10 as a therapy for ... for atopic dermatitis and psoriasis. This ...
(Date:10/22/2014)... NORWALK, Conn. , Oct. 22, 2014  Recently ... (GERD) have bolstered the already substantial database of evidence. ... and adoption of Stretta therapy for sufferers ... of clinical evidence supporting Stretta therapy as ... coverage policies that make Stretta therapy available to nearly ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014   ... and WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials ... Under the terms of the collaboration, Foundation Medicine will ... of Foundation Medicine,s FoundationOne® assay at the WuXi Genome ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
Cached News: